ACHIEVE LIFE SCIENCES, INC. stock analysis

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements

Ticker: ACHV
Exchange: Nasdaq
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded ACHIEVE LIFE SCIENCES, INC. at 7.75 USD on 2026-09-28T20:00:01.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2021-09-30 through 2026-08-14 across 1218 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying ACHIEVE LIFE SCIENCES, INC. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.